Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$0 commission on every transaction. Hope Fidelity keeps it that way. I used to pay in the thousands in commission in one year.
Looks like you are optimistic this time Stonk.
With Fidelity, I don’t need to wait. The moment after I initiated the transfer, the fund is available immediately to buy any security.
2M volume already? More people buy or sell?
Oh wow FeMike’s price prediction.
Those armies of fudsters are needed to maintain the illusions that NWBO is just a 30 cents stock. It is just very obvious.
You make me chuckled.
This is not an easy buy ATL for you I believe. I did the same and it was not easy for me. But you prove your conviction in NWBO.
I see. Brystol acquired Celgene with $74 B offers.
Oh no. Sky, if that is true, LP might have a vision to be another BP. Unlike the short, I believe LP know exactly what is the value of tissue agnostics platform with automated manufacturing for all kinds of DCs, Car-T.
Who is willing to guess?
1T?
Absolutely agree Flip. Being rigorously validated is not really a bad thing. The next regulators don’t have to do the same validation again because the heavy lifting has been done by MHRA.
Doc,
Mr Avistin did it again. He is very consistent in this regards. Hm.. inquiriq mind is looking for a reason. What is behind the “a” and “i” got misplaced? Is that unintentional mistake?
Hm..
Flip, I agree. $23 Billion looks very affordable for Lily or Novo.
Lily just the last 3 years has enjoyed 260% stock price increases. With that blockbuster performance, Lily can afford a blockbuster BO without really scratching the surface.
IMHO.
Flip that $800B market cap really change my perspective.
Let’s see. Hmm.. how about if we start with an $80 Billion offer? It still looks just a 10% of the market cap of that $800 B behemoth predicted to be the first health care company to reach $1T.
Is an $80Billion an offer too high for tissue agnostic? I don’t think so.
Is $80Billion BO an offer that cannot be ignored by LP? I think so.
Hope I don’t scare shorts this early morning hour.
We will see which group is right. The bulls or the bears?
That Investor082 doesn’t have a clue about FlaskWorks.
Are you a short? If you are a short, I can understand the context of your repeated comments. Dangling carrots? 50 cents after approval? All make sense. Because you wanted to cover your shorts, right?
Because you are a short. Enough said.
“There will be no short squeeze.”
What do you think? $7 - $28.
Full of carrots?
Let's adjust the valuation based on your updated assumptions:
— Andrew Caravello, DO (@andrewcaravello) September 5, 2024
- **Outstanding Shares (OS)**: 1.5 billion shares (instead of 1 billion).
- **Treatment Price**: $175,000 per patient (instead of $250,000).
### 1. **Revenue Estimate**:
With the same assumption that 10-20% of global…
Long readings but worth it. High quality paper.
He eventually buy I thought so when he could not convince longs to sell on the cheap.
Nice try!
What? You need to answer that questions yourself.
Yes apples with Aapl symbol. Certainly. :)
EDEN is the key.
LP knows EDEN is not carrots.
Some think LP just dangling carrots.
Did they know EDEN?
I suspect they are clueless about EDEN. Did their boss know about EDEN? Probably clueless too.
You need to start due diligence yourself to grow conviction. Read the 10k. Listen to ASM carefully. Then draw your own conclusions. If you need help, ask chatGPT, Gemini, or Grox. They are smart. Tap this opportunity while it is still free.
I think on the contrary BP is willing to give an offer if NWBO can get approval and NWBO can get FlaskWorks development completed and validated.
Right?
Without FlaskWorks validated, BP will not dare.
Why?
Because immunotherapy is not BP’s strong suit.
Of course LP needs to appease BP’s concerns first.
I think this is logical.
So I do believe BP knows but LP needs to do the homework first.
Who knows all parties need to sign NDA.
It doesn’t mean nothing is not being negotiated right?
It’s not guessing. It’s already there in 10Q, 10K and ASM.
But still some folks here still do not see what kind of foundation being built here.
They think always price.
Of course price is important but NWBO at this juncture care beyond price.
You need to backup price with something right?
Something of quality?
Something of substance?
Something that can solve huge problems?
Once that achieves, prices will automatically come.
Will BP appreciate what LP is preparing? Some say No. Some say Of Course. Which one are you?
rGBM cases in UK annually according to chatgpt.
In the UK, recurrent glioblastoma multiforme (rGBM) cases are more challenging to quantify precisely because they depend on factors like initial treatment success and patient survival rates. However, it's estimated that a significant proportion of the approximately 2,000 to 2,500 annual GBM cases will eventually recur, with recurrence rates often cited as high as 90% within two years. This suggests that there could be around 1,800 to 2,250 rGBM cases annually in the UK, though the exact number can vary based on patient outcomes and advancements in treatment.
Again I encourage you to use Inversion techniques then you know what is in LP’s mind.
If your reasoning is only about price, price and price, you can’t see what is the most important at this juncture.
Once the core foundation has been built then that will take care of the price.
What is the core foundation that is being prepared by LP?
Care to guess?
$15 M/$200k = 75 patients being treated in a year.
I think your estimated number is too conservative. After approval at hand, NWBO will campaign. That can make a big impact in recognition. Who knows that immunotherapy can cure GBM? Majority of people do not know. You will be surprised when people know.
In the UK, there are approximately **2,000 to 2,500 new cases** of glioblastoma multiforme (GBM) diagnosed each year. This makes it the most common primary malignant brain tumor in adults in the country.
You don’t know what is in LP’s mind. LP cares what is most important. What is most important for NWBO at this juncture? Stock prices? You might think stock prices right?
Use inversion techniques. Then you know what is in LP’s mind.
Name BP in the world that buys a pre revenue biotech before approv
ChatGPT:
It’s uncommon for big pharmaceutical companies (BPs) to acquire pre-revenue biotech firms before their products receive regulatory approval, but it does happen, particularly when the biotech's technology or pipeline shows significant promise. Here are a few examples of such acquisitions:
1. **Gilead Sciences / Kite Pharma (2017)**: Gilead acquired Kite Pharma for $11.9 billion while Kite was still a pre-revenue company focused on developing CAR-T therapies for cancer. Kite's lead product, Yescarta, was approved shortly after the acquisition.
2. **Roche / Flatiron Health (2018)**: Roche acquired Flatiron Health for $1.9 billion. Although Flatiron wasn't developing drugs, it was a pre-revenue company focused on healthcare data and software, which Roche believed could enhance its oncology pipeline.
3. **Bristol-Myers Squibb / Juno Therapeutics (2018)**: Bristol-Myers Squibb acquired Juno Therapeutics for $9 billion while Juno was still a pre-revenue company working on CAR-T therapies for cancer.
4. **Novartis / AveXis (2018)**: Novartis acquired AveXis for $8.7 billion. At the time of acquisition, AveXis was pre-revenue and its gene therapy for spinal muscular atrophy, Zolgensma, was not yet approved.
These acquisitions highlight the significant interest major pharmaceutical companies have in innovative biotech firms, even before their products have received approval, due to the potential for high-impact therapies that can transform markets.
The reality is the expected demands when the word is out are going to be huge. Therefore FlaskWorks is the answer. Glad you are not advising LP. But LP of course knows better what are important. Yes I bet LP would speak in conferences again soon after all the important things have been approved.
$90 million revenue forecast is quite impressive. Care to estimate the GM?
On the contrary BP will be desperate because they know what NWBO owns. BP are not listening to you. They have scientists who know NWBO and already let their Bosses’Boss know.
Yes of course she would rally the shareholders after approval at hand. No worries.
If the ticker symbol change to NWAV because NWBO and Advent merger. I am no worried about those legit short sellers. Because we know who they are and number of shares they shorted. But, what about the naked shorts? Do we know them? Do we know the exact number of shares they naked shorted?
These guys can’t just walk away as if nothing happens. They have to return the shares they shorted.
Seems like a logical move.